Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 382

1.

Author Correction: Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes.

Rombaut D, Chiu HS, Decaesteker B, Everaert C, Yigit N, Peltier A, Janoueix-Lerosey I, Bartenhagen C, Fischer M, Roberts S, D'Haene N, De Preter K, Speleman F, Denecker G, Sumazin P, Vandesompele J, Lefever S, Mestdagh P.

Sci Rep. 2019 Jul 17;9(1):10536. doi: 10.1038/s41598-019-46785-6.

2.

SMARTer single cell total RNA sequencing.

Verboom K, Everaert C, Bolduc N, Livak KJ, Yigit N, Rombaut D, Anckaert J, Lee S, Venø MT, Kjems J, Speleman F, Mestdagh P, Vandesompele J.

Nucleic Acids Res. 2019 Sep 19;47(16):e93. doi: 10.1093/nar/gkz535.

PMID:
31216024
3.

Publisher Correction: In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors.

Vanhauwaert S, Decaesteker B, De Brouwer S, Leonelli C, Durinck K, Mestdagh P, Vandesompele J, Sermon K, Denecker G, Van Neste C, Speleman F, De Preter K.

Sci Rep. 2019 Jun 4;9(1):8360. doi: 10.1038/s41598-019-44435-5.

4.

DREAM target reactivation by core transcriptional regulators supports neuroblastoma growth.

Decaesteker B, De Preter K, Speleman F.

Mol Cell Oncol. 2019 Feb 3;6(2):1565470. doi: 10.1080/23723556.2019.1565470. eCollection 2019.

PMID:
31131299
5.

Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes.

Rombaut D, Chiu HS, Decaesteker B, Everaert C, Yigit N, Peltier A, Janoueix-Lerosey I, Bartenhagen C, Fischer M, Roberts S, D'Haene N, De Preter K, Speleman F, Denecker G, Sumazin P, Vandesompele J, Lefever S, Mestdagh P.

Sci Rep. 2019 Apr 5;9(1):5685. doi: 10.1038/s41598-019-42107-y. Erratum in: Sci Rep. 2019 Jul 17;9(1):10536.

6.

Purification of high-quality RNA from a small number of fluorescence activated cell sorted zebrafish cells for RNA sequencing purposes.

Loontiens S, Depestel L, Vanhauwaert S, Dewyn G, Gistelinck C, Verboom K, Van Loocke W, Matthijssens F, Willaert A, Vandesompele J, Speleman F, Durinck K.

BMC Genomics. 2019 Mar 20;20(1):228. doi: 10.1186/s12864-019-5608-2.

7.

A mechanistic classification of clinical phenotypes in neuroblastoma.

Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F, Schulte JH, Peifer M, Fischer M.

Science. 2018 Dec 7;362(6419):1165-1170. doi: 10.1126/science.aat6768.

PMID:
30523111
8.

ALK positively regulates MYCN activity through repression of HBP1 expression.

Claeys S, Denecker G, Durinck K, Decaesteker B, Mus LM, Loontiens S, Vanhauwaert S, Althoff K, Wigerup C, Bexell D, Dolman E, Henrich KO, Wehrmann L, Westerhout EM, Demoulin JB, Kumps C, Van Maerken T, Laureys G, Van Neste C, De Wilde B, De Wever O, Westermann F, Versteeg R, Molenaar JJ, Påhlman S, Schulte JH, De Preter K, Speleman F.

Oncogene. 2019 Apr;38(15):2690-2705. doi: 10.1038/s41388-018-0595-3. Epub 2018 Dec 11.

PMID:
30538293
9.

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P, Vandesompele J.

JCI Insight. 2018 Dec 6;3(23). pii: 97021. doi: 10.1172/jci.insight.97021.

10.

In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors.

Vanhauwaert S, Decaesteker B, De Brouwer S, Leonelli C, Durinck K, Mestdagh P, Vandesompele J, Sermon K, Denecker G, Van Neste C, Speleman F, De Preter K.

Sci Rep. 2018 Nov 30;8(1):17468. doi: 10.1038/s41598-018-35868-5. Erratum in: Sci Rep. 2019 Jun 4;9(1):8360.

11.

Long noncoding RNA expression profiling in cancer: Challenges and opportunities.

Lorenzi L, Avila Cobos F, Decock A, Everaert C, Helsmoortel H, Lefever S, Verboom K, Volders PJ, Speleman F, Vandesompele J, Mestdagh P.

Genes Chromosomes Cancer. 2019 Apr;58(4):191-199. doi: 10.1002/gcc.22709. Epub 2019 Jan 20. Review.

PMID:
30461116
12.

Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.

Emdal KB, Pedersen AK, Bekker-Jensen DB, Lundby A, Claeys S, De Preter K, Speleman F, Francavilla C, Olsen JV.

Sci Signal. 2018 Nov 20;11(557). pii: eaap9752. doi: 10.1126/scisignal.aap9752.

PMID:
30459283
13.

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.

Decaesteker B, Denecker G, Van Neste C, Dolman EM, Van Loocke W, Gartlgruber M, Nunes C, De Vloed F, Depuydt P, Verboom K, Rombaut D, Loontiens S, De Wyn J, Kholosy WM, Koopmans B, Essing AHW, Herrmann C, Dreidax D, Durinck K, Deforce D, Van Nieuwerburgh F, Henssen A, Versteeg R, Boeva V, Schleiermacher G, van Nes J, Mestdagh P, Vanhauwaert S, Schulte JH, Westermann F, Molenaar JJ, De Preter K, Speleman F.

Nat Commun. 2018 Nov 19;9(1):4866. doi: 10.1038/s41467-018-06699-9.

14.

Meta-mining of copy number profiles of high-risk neuroblastoma tumors.

Depuydt P, Koster J, Boeva V, Hocking TD, Speleman F, Schleiermacher G, De Preter K.

Sci Data. 2018 Oct 30;5:180240. doi: 10.1038/sdata.2018.240.

15.

Pinpointing a potential role for CLEC12B in cancer predisposition through familial exome sequencing.

Derpoorter C, Vandepoele K, Diez-Fraile A, Vandemeulebroecke K, De Wilde B, Speleman F, Van Roy N, Lammens T, Laureys G.

Pediatr Blood Cancer. 2019 Feb;66(2):e27513. doi: 10.1002/pbc.27513. Epub 2018 Oct 23.

PMID:
30350915
16.

A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.

Verboom K, Van Loocke W, Volders PJ, Decaesteker B, Cobos FA, Bornschein S, de Bock CE, Atak ZK, Clappier E, Aerts S, Cools J, Soulier J, Taghon T, Van Vlierberghe P, Vandesompele J, Speleman F, Durinck K.

Haematologica. 2018 Dec;103(12):e585-e589. doi: 10.3324/haematol.2018.190587. Epub 2018 Jun 28. No abstract available.

17.

LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.

Dorneburg C, Fischer M, Barth TFE, Mueller-Klieser W, Hero B, Gecht J, Carter DR, de Preter K, Mayer B, Christner L, Speleman F, Marshall GM, Debatin KM, Beltinger C.

Clin Cancer Res. 2018 Nov 15;24(22):5772-5783. doi: 10.1158/1078-0432.CCR-17-2578. Epub 2018 Jun 20.

PMID:
29925504
18.

Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice.

Renard M, Vanhauwaert S, Vanhomwegen M, Rihani A, Vandamme N, Goossens S, Berx G, Van Vlierberghe P, Haigh JJ, Decaesteker B, Van Laere J, Lambertz I, Speleman F, Vandesompele J, Willaert A.

Sci Rep. 2018 May 16;8(1):7642. doi: 10.1038/s41598-018-25389-6.

19.

Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia.

Garcia EG, Iyer S, Garcia SP, Loontiens S, Sadreyev RI, Speleman F, Langenau DM.

Leukemia. 2018 Aug;32(8):1860-1865. doi: 10.1038/s41375-018-0130-0. Epub 2018 Apr 18. No abstract available.

20.

Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.

Ooi CY, Carter DR, Liu B, Mayoh C, Beckers A, Lalwani A, Nagy Z, De Brouwer S, Decaesteker B, Hung TT, Norris MD, Haber M, Liu T, De Preter K, Speleman F, Cheung BB, Marshall GM.

Cancer Res. 2018 Jun 15;78(12):3122-3134. doi: 10.1158/0008-5472.CAN-17-3034. Epub 2018 Apr 2.

21.

Promoter-associated proteins of EPAS1 identified by enChIP-MS - A putative role of HDX as a negative regulator.

Hamidian A, Vaapil M, von Stedingk K, Fujita T, Persson CU, Eriksson P, Veerla S, De Preter K, Speleman F, Fujii H, Påhlman S, Mohlin S.

Biochem Biophys Res Commun. 2018 May 5;499(2):291-298. doi: 10.1016/j.bbrc.2018.03.150. Epub 2018 Mar 26.

PMID:
29577908
22.

A high-throughput 3' UTR reporter screening identifies microRNA interactomes of cancer genes.

Van Peer G, Mets E, Claeys S, De Punt I, Lefever S, Ongenaert M, Rondou P, Speleman F, Mestdagh P, Vandesompele J.

PLoS One. 2018 Mar 9;13(3):e0194017. doi: 10.1371/journal.pone.0194017. eCollection 2018.

23.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.

24.

The mutational landscape of MYCN, Lin28b and ALKF1174L driven murine neuroblastoma mimics human disease.

De Wilde B, Beckers A, Lindner S, Kristina A, De Preter K, Depuydt P, Mestdagh P, Sante T, Lefever S, Hertwig F, Peng Z, Shi LM, Lee S, Vandermarliere E, Martens L, Menten B, Schramm A, Fischer M, Schulte J, Vandesompele J, Speleman F.

Oncotarget. 2017 Dec 22;9(9):8334-8349. doi: 10.18632/oncotarget.23614. eCollection 2018 Feb 2.

25.

Vehicle development, pharmacokinetics and toxicity of the anti-invasive agent 4-fluoro-3',4',5'-trimethoxychalcone in rodents.

Mus LM, Denecker G, Speleman F, Roman BI.

PLoS One. 2018 Feb 22;13(2):e0192548. doi: 10.1371/journal.pone.0192548. eCollection 2018.

26.

Correction to: Epigenetic regulation of neuroblastoma development.

Durinck K, Speleman F.

Cell Tissue Res. 2018 May;372(2):443. doi: 10.1007/s00441-018-2811-4.

PMID:
29396592
27.

Epigenetic regulation of neuroblastoma development.

Durinck K, Speleman F.

Cell Tissue Res. 2018 May;372(2):309-324. doi: 10.1007/s00441-017-2773-y. Epub 2018 Jan 19. Review. Erratum in: Cell Tissue Res. 2018 Feb 2;:.

PMID:
29350283
28.

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

Claeys S, Denecker G, Cannoodt R, Kumps C, Durinck K, Speleman F, De Preter K.

Oncotarget. 2017 Nov 6;8(63):106820-106832. doi: 10.18632/oncotarget.22423. eCollection 2017 Dec 5.

29.

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.

Van Goethem A, Yigit N, Moreno-Smith M, Vasudevan SA, Barbieri E, Speleman F, Shohet J, Vandesompele J, Van Maerken T.

Oncotarget. 2017 Jul 4;8(34):57047-57057. doi: 10.18632/oncotarget.18982. eCollection 2017 Aug 22.

30.

Comprehensive miRNA expression profiling in human T-cell acute lymphoblastic leukemia by small RNA-sequencing.

Wallaert A, Van Loocke W, Hernandez L, Taghon T, Speleman F, Van Vlierberghe P.

Sci Rep. 2017 Aug 11;7(1):7901. doi: 10.1038/s41598-017-08148-x.

31.

Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients.

Van Roy N, Van Der Linden M, Menten B, Dheedene A, Vandeputte C, Van Dorpe J, Laureys G, Renard M, Sante T, Lammens T, De Wilde B, Speleman F, De Preter K.

Clin Cancer Res. 2017 Oct 15;23(20):6305-6314. doi: 10.1158/1078-0432.CCR-17-0675. Epub 2017 Jul 14.

32.

Long non-coding RNAs in leukemia: biology and clinical impact.

Lammens T, Durinck K, Wallaert A, Speleman F, Van Vlierberghe P.

Curr Opin Hematol. 2017 Jul;24(4):353-358. doi: 10.1097/MOH.0000000000000354. Review.

PMID:
28441150
33.

T-ALL and thymocytes: a message of noncoding RNAs.

Wallaert A, Durinck K, Taghon T, Van Vlierberghe P, Speleman F.

J Hematol Oncol. 2017 Mar 7;10(1):66. doi: 10.1186/s13045-017-0432-0. Review.

34.

Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples.

Van Goethem A, Yigit N, Everaert C, Moreno-Smith M, Mus LM, Barbieri E, Speleman F, Mestdagh P, Shohet J, Van Maerken T, Vandesompele J.

Sci Rep. 2016 Nov 30;6:37876. doi: 10.1038/srep37876.

35.

Targeting tachykinin receptors in neuroblastoma.

Henssen AG, Odersky A, Szymansky A, Seiler M, Althoff K, Beckers A, Speleman F, Schäfers S, De Preter K, Astrahanseff K, Struck J, Schramm A, Eggert A, Bergmann A, Schulte JH.

Oncotarget. 2017 Jan 3;8(1):430-443. doi: 10.18632/oncotarget.13440.

36.

Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia.

Ghazavi F, De Moerloose B, Van Loocke W, Wallaert A, Helsmoortel HH, Ferster A, Bakkus M, Plat G, Delabesse E, Uyttebroeck A, Van Nieuwerburgh F, Deforce D, Van Roy N, Speleman F, Benoit Y, Lammens T, Van Vlierberghe P.

Oncotarget. 2016 Nov 8;7(45):73769-73780. doi: 10.18632/oncotarget.12063.

37.

Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait.

Decock A, Ongenaert M, De Wilde B, Brichard B, Noguera R, Speleman F, Vandesompele J.

Epigenetics. 2016 Oct 2;11(10):761-771. doi: 10.1080/15592294.2016.1226739.

38.

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.

Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, de Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wünschel J, Pfeil S, Ercu M, Künkele A, Hu J, Thole T, Schweizer L, Mechtersheimer G, Carter D, Cheung BB, Popanda O, von Deimling A, Koster J, Versteeg R, Schwab M, Marshall GM, Speleman F, Erb U, Zoeller M, Allgayer H, Simon T, Fischer M, Kulozik AE, Eggert A, Witt O, Schulte JH, Deubzer HE.

Oncotarget. 2016 Oct 11;7(41):66344-66359. doi: 10.18632/oncotarget.11662.

39.

RT-qPCR gene expression analysis in zebrafish: Preanalytical precautions and use of expressed repetitive elements for normalization.

Vanhauwaert S, Lefever S, Coucke P, Speleman F, De Paepe A, Vandesompele J, Willaert A.

Methods Cell Biol. 2016;135:329-42. doi: 10.1016/bs.mcb.2016.02.002. Epub 2016 Mar 4.

PMID:
27443934
40.

Neuroblastoma: A Tough Nut to Crack.

Speleman F, Park JR, Henderson TO.

Am Soc Clin Oncol Educ Book. 2016;35:e548-57. doi: 10.14694/EDBK_159169. Review.

41.

Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia.

Wallaert A, Durinck K, Van Loocke W, Van de Walle I, Matthijssens F, Volders PJ, Avila Cobos F, Rombaut D, Rondou P, Mestdagh P, Vandesompele J, Poppe B, Taghon T, Soulier J, Van Vlierberghe P, Speleman F.

Leukemia. 2016 Sep;30(9):1927-30. doi: 10.1038/leu.2016.82. Epub 2016 Apr 22. No abstract available.

PMID:
27168467
42.

GATA3 induces human T-cell commitment by restraining Notch activity and repressing NK-cell fate.

Van de Walle I, Dolens AC, Durinck K, De Mulder K, Van Loocke W, Damle S, Waegemans E, De Medts J, Velghe I, De Smedt M, Vandekerckhove B, Kerre T, Plum J, Leclercq G, Rothenberg EV, Van Vlierberghe P, Speleman F, Taghon T.

Nat Commun. 2016 Apr 6;7:11171. doi: 10.1038/ncomms11171.

43.

Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.

Carter DR, Sutton SK, Pajic M, Murray J, Sekyere EO, Fletcher J, Beckers A, De Preter K, Speleman F, George RE, Haber M, Norris MD, Cheung BB, Marshall GM.

Mol Oncol. 2016 Jun;10(6):866-78. doi: 10.1016/j.molonc.2016.02.004. Epub 2016 Mar 2.

44.

LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19.

Helsmoortel HH, De Moerloose B, Pieters T, Ghazavi F, Bresolin S, Cavé H, de Vries A, de Haas V, Flotho C, Labarque V, Niemeyer C, De Paepe P, Van Roy N, Stary J, van den Heuvel-Eibrink MM, Benoit Y, Schulte J, Goossens S, Berx G, Haigh JJ, Speleman F, Van Vlierberghe P, Lammens T.

Haematologica. 2016 Jun;101(6):e240-4. doi: 10.3324/haematol.2016.143818. Epub 2016 Mar 11. No abstract available.

45.

DNA methylation profiling of primary neuroblastoma tumors using methyl-CpG-binding domain sequencing.

Decock A, Ongenaert M, Van Criekinge W, Speleman F, Vandesompele J.

Sci Data. 2016 Feb 2;3:160004. doi: 10.1038/sdata.2016.4.

46.

LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia.

Helsmoortel HH, Bresolin S, Lammens T, Cavé H, Noellke P, Caye A, Ghazavi F, de Vries A, Hasle H, Labarque V, Masetti R, Stary J, van den Heuvel-Eibrink MM, Philippé J, Van Roy N, Benoit Y, Speleman F, Niemeyer C, Flotho C, Basso G, Te Kronnie G, Van Vlierberghe P, De Moerloose B.

Blood. 2016 Mar 3;127(9):1163-72. doi: 10.1182/blood-2015-09-667808. Epub 2015 Dec 28.

PMID:
26712910
47.

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA; Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J.

Oncotarget. 2016 Jan 12;7(2):1960-72. doi: 10.18632/oncotarget.6477.

48.

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.

Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schäfers S, Bell E, Nortmeyer M, Westermann F, De Preter K, Florin A, Heukamp L, Spruessel A, Astrahanseff K, Lindner S, Sadowski N, Schramm A, Astorgues-Xerri L, Riveiro ME, Eggert A, Cvitkovic E, Schulte JH.

Clin Cancer Res. 2016 May 15;22(10):2470-81. doi: 10.1158/1078-0432.CCR-15-1449. Epub 2015 Dec 2.

49.

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, Sutton S, Kalla H, Syed S, Gifford AJ, Issaeva N, Biktasova A, Atmadibrata B, Sun Y, Sokolowski N, Ling D, Kim PY, Webber H, Clark A, Ruhle M, Liu B, Oberthuer A, Fischer M, Byrne J, Saletta F, Thwe le M, Purmal A, Haderski G, Burkhart C, Speleman F, De Preter K, Beckers A, Ziegler DS, Liu T, Gurova KV, Gudkov AV, Norris MD, Haber M, Marshall GM.

Sci Transl Med. 2015 Nov 4;7(312):312ra176. doi: 10.1126/scitranslmed.aab1803.

50.

Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma.

Rihani A, Vandesompele J, Speleman F, Van Maerken T.

Cancer Cell Int. 2015 Jul 30;15:76. doi: 10.1186/s12935-015-0224-y. eCollection 2015.

Supplemental Content

Loading ...
Support Center